<rp id="1xfe3"></rp><span id="1xfe3"></span>
<td id="1xfe3"><tr id="1xfe3"><th id="1xfe3"></th></tr></td>
  1. <source id="1xfe3"></source>
    <p id="1xfe3"><ins id="1xfe3"><th id="1xfe3"></th></ins></p>
      <td id="1xfe3"><optgroup id="1xfe3"><th id="1xfe3"></th></optgroup></td>
    1. <i id="1xfe3"><ins id="1xfe3"></ins></i>

      <noscript id="1xfe3"><tbody id="1xfe3"></tbody></noscript>
        <small id="1xfe3"><dl id="1xfe3"></dl></small>

      • 精品视频久久久久久_色乱码一区二区三区_老乱女中文字幕熟女熟妇_国产精品一区在线播放_来一水AV@lysav

        您好!歡迎訪問上海根生生物科技有限公司網(wǎng)站!
        全國服務(wù)咨詢熱線:

        15216781845

        當前位置:首頁 > 產(chǎn)品中心 > > 其它耗材與試劑 > ant-mpt進口支原體清除劑*Invivogen Plasmocin™ treatmen

        進口支原體清除劑*Invivogen Plasmocin™ treatmen

        簡要描述:進口支原體清除劑*Invivogen Plasmocin™ treatmen,Invivogen Plasmocin™ treatment支原體清除試劑規(guī)格50 mg (2 x 1 ml)現(xiàn)貨,詳細產(chǎn)品信息請

        • 產(chǎn)品型號:ant-mpt
        • 廠商性質(zhì):代理商
        • 更新時間:2024-04-16
        • 訪  問  量:7382

        詳細介紹

        進口支原體清除劑*Invivogen Plasmocin™ treatmen

         

        Plasmocin™

        Mycoplasma Removal Agent

        Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria. 
        PlasmocinPlasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures.
        More info on Mycoplasma eradication

        Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. 
        The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are compley absent in eukaryotic cells.

        Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.

         

        • Specifications
        • Docs
        • Contents
        • Description
        • Details
        • Citations

        - Active on both free mycoplasmas and intracellular forms
        - No resistance in liquid cultures of mycoplasmas
        - No apparent adverse effect on cellular metabolism
        - Active at low concentrations on a broad range of Gram positive and negative bacteria
        - Eliminates mycoplasma in as little as 2 weeks
        - Treat up to 25 cell lines in T75

         

        • TDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp)
        • TDS Plasmocin™ treatment : 50 mg (2 x 1 ml) (ant-mpt)
        • MSDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp) , 50 mg (2 x 1 ml) (ant-mpt)

         

        Plasmocin™ is provided as a yellow solution at different concentrations:

        -  25 mg/ml (Plasmocin™Treatment)

        -  2.5 mg/ml (Plasmocin™ Prophylactic)

        In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.

        In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.

        No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.

        Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.

        Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.

        Comparison of the most common anti-mycoplasma agents [1-3]

        ProductSupplierTreatmentEase of useEfficacyCytotoxicityResistance
        BM-CyclinRoche3 weeks-+++++/-
        CiprobayBayer12 to 20 days++++/-+
        MRAICN1 to 2 weeks++++/-+
        PlasmocinInvivoGen2 weeks+++++/--

        Antibiotics commonly used in cell culture are inactive on mycoplasma (e.g. penicillins and streptomycin). Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA.
        Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin (Roche) contains a macrolide and a tetracycline, Ciprobay (Bayer, available only with a prescription) and MRA (ICN) are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].

        1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34.
        2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A(11-12):708-10
        3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A(5):344-7

         

        Recent articles using Plasmocin™

         

         

        • 2012 - J Virol Methods., Epub ahead of print
          Mycoplasma removal: Simple curative methods for viral supernatants.
          Baronti C, Pastorino B, Charrel R, de Lamballerie X
        • 2011 - Mol Pharmacol., 80(6):1066-75
          Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy.
          Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
        • 2011 - J Immunol., 186(12):6822-6829
          Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
          Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
        • 2012 - J. Biol. Chem., 287: 8082 - 8091
          Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 (TRPML1) leads to cathepsin B-dependent apoptosis.
          Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
        • 2012 - Immunity, 36(3):464-476
          An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages.
          Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C

         

         

        ORDERING

        Plasmocin™ prophylactic

        DescriptionRemoval agent to prevent mycoplasma contamination
        Cat. Codeant-mpp
        Unit Size25 mg (10 x 1 ml)
        PricePlease contact our distributor

         

        • TDS
        • MSDS

         

        Plasmocin™ treatment

        DescriptionRemoval agent to eliminate mycoplasmas
        Cat. Codeant-mpt
        Unit Size50 mg (2 x 1 ml)
        PricePlease contact our distributor

         

        • TDS
        • MSDS

         

        YOU MAY ALSO NEED

        PlasmoTest™Detection of mycoplasma contamination in cell culture kit
        Normocin™Antimicrobial agent for prevention against Mycoplasma, Bacteria and Fungi
        Fungin™Antimicrobial agent for prevention and elimination of Fungi
        G418Selection antibiotic for the neo gene
        PuromycinSelection antibiotic for the pac gene

        產(chǎn)品咨詢

        留言框

        • 產(chǎn)品:

        • 您的單位:

        • 您的姓名:

        • 聯(lián)系電話:

        • 常用郵箱:

        • 省份:

        • 詳細地址:

        • 補充說明:

        • 驗證碼:

          請輸入計算結(jié)果(填寫阿拉伯數(shù)字),如:三加四=7
        上海根生生物科技有限公司
        地址:上海市奉賢區(qū)南橋鎮(zhèn)南橋路377號1幢
        郵箱:genshengtech@163.com
        傳真:86-021-64190979
        關(guān)注我們
        歡迎您關(guān)注我們的微信公眾號了解更多信息:
        歡迎您關(guān)注我們的微信公眾號
        了解更多信息
        精品视频久久久久久_色乱码一区二区三区_老乱女中文字幕熟女熟妇_国产精品一区在线播放_来一水AV@lysav
        <rp id="1xfe3"></rp><span id="1xfe3"></span>
        <td id="1xfe3"><tr id="1xfe3"><th id="1xfe3"></th></tr></td>
        1. <source id="1xfe3"></source>
          <p id="1xfe3"><ins id="1xfe3"><th id="1xfe3"></th></ins></p>
            <td id="1xfe3"><optgroup id="1xfe3"><th id="1xfe3"></th></optgroup></td>
          1. <i id="1xfe3"><ins id="1xfe3"></ins></i>

            <noscript id="1xfe3"><tbody id="1xfe3"></tbody></noscript>
              <small id="1xfe3"><dl id="1xfe3"></dl></small>

            • 犍为县| 渭源县| 霍林郭勒市| 安化县| 广安市| 当阳市| 灌南县| 苗栗县| 新建县| 南丰县| 廉江市| 商城县| 松江区| 榆树市| 夹江县| 鸡泽县| 丹巴县| 龙川县| 宜川县| 阿克陶县| 塔河县| 兰溪市| 温州市| 乐山市| 开江县| 吴江市| 榆社县| 南江县| 吉隆县| 龙游县| 洛阳市| 城固县| 久治县| 开化县| 高密市| 红安县| 扶风县| 清涧县| 常宁市| 六枝特区| 石泉县|